JAPAN SCIENCE AND TECHNOLOGY AGENCY
🇮🇳India
Clinical Trials
16
Active:0
Completed:10
Trial Phases
3 Phases
Phase 1:1
Phase 3:1
Not Applicable:14
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
Not Applicable
14 (87.5%)Phase 1
1 (6.3%)Phase 3
1 (6.3%)Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study
Phase 3
Completed
- Conditions
- Posttraumatic Stress DisorderTrauma
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2014-01-22
- Lead Sponsor
- Japan Science and Technology Agency
- Target Recruit Count
- 110
- Registration Number
- NCT00671099
- Locations
- 🇯🇵
National Disaster Medical Center, Tachikawa, Tokyo, Japan
Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-01 Study
Phase 1
Completed
- Conditions
- TraumaPosttraumatic Stress Disorder
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Japan Science and Technology Agency
- Target Recruit Count
- 15
- Registration Number
- NCT00671489
- Locations
- 🇯🇵
National Disaster Medical Center, Tachikawa, Tokyo ,Japan, Tachikawa, Tokyo, Japan
News
FELIQS Secures $9 Million Series A to Advance Novel ROP Prevention Therapy FLQ-101
FELIQS Corporation completed a $9 million Series A funding round co-led by a major American pharmaceutical company and Beyond Next Ventures to advance FLQ-101 for retinopathy of prematurity prevention.
Alpha Fusion and Curadh Form Strategic Partnership to Advance Astatine-211 Radiopharmaceuticals
Alpha Fusion and Curadh MTR announced a strategic partnership including a joint venture to advance global development of Astatine-211 based radiopharmaceuticals for cancer therapy.